Literature DB >> 8197161

The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

R N Bamford1, A J Grant, J D Burton, C Peters, G Kurys, C K Goldman, J Brennan, E Roessler, T A Waldmann.   

Abstract

Late-phase human T-cell lymphotropic virus I-associated adult T-cell leukemia cells express IL-2 receptors (IL-2R) but no longer produce IL-2. We have reported that the IL-2-independent adult T-cell leukemia line HuT-102 secretes a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and lymphokine-activated killer cell activity. Stimulation of proliferation of the cytokine-dependent human T-cell line Kit-225 mediated by HuT-102-conditioned medium or by 3200-fold-purified IL-T was not blocked by the addition of antibodies against IL-2 or IL-2R alpha subunit. However, IL-T-mediated stimulation of this human T-cell line was inhibited by addition of Mik-beta 1, an antibody that binds specifically to IL-2R beta subunit. In addition, the activation of large granular lymphocytes to lymphokine-activated killer cells mediated by IL-T-containing conditioned medium was not blocked by antibodies directed toward IL-2 or IL-2 alpha but was inhibited by an antibody to IL-2R beta, suggesting the requirement of this receptor subunit for IL-T action. This conclusion was confirmed using an IL-3-dependent murine myeloid precursor cell line, 32D, that expresses IL-2R alpha and IL-2R gamma, but not IL-2R beta. Neither IL-2 nor IL-T stimulated 32D cell proliferation. However, after transfection with the gene encoding human IL-2R beta, 32D beta cells proliferated on addition of either cytokine. The IL-T-mediated stimulation of 32D beta proliferation was inhibited by an anti-IL-2R beta antibody but not by an anti-IL-2 antibody. Thus, the IL-T-mediated stimulation of T-cell and lymphokine-activated killer cell activation requires the expression of the IL-2R beta subunit.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8197161      PMCID: PMC43905          DOI: 10.1073/pnas.91.11.4940

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

Authors:  M Tsudo; R W Kozak; C K Goldman; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Human B lymphocytes express the p75 component of the interleukin 2 receptor.

Authors:  C G Begley; J D Burton; M Tsudo; B H Brownstein; J L Ambrus; T A Waldmann
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

Review 3.  The multi-subunit interleukin-2 receptor.

Authors:  T A Waldmann
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

4.  Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies.

Authors:  M Tsudo; F Kitamura; M Miyasaka
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

5.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

6.  The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.

Authors:  M Tsudo; C K Goldman; K F Bongiovanni; W C Chan; E F Winton; M Yagita; E A Grimm; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia.

Authors:  M Maeda; N Arima; Y Daitoku; M Kashihara; H Okamoto; T Uchiyama; K Shirono; M Matsuoka; T Hattori; K Takatsuki
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

8.  Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2.

Authors:  J Y Djeu; J H Liu; S Wei; H Rui; C A Pearson; W J Leonard; D K Blanchard
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

Review 9.  Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma.

Authors:  T A Waldmann
Journal:  J Natl Cancer Inst       Date:  1989-06-21       Impact factor: 13.506

10.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

View more
  108 in total

1.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.

Authors:  SangKon Oh; Jay A Berzofsky; Donald S Burke; Thomas A Waldmann; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

3.  IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory.

Authors:  Patrick R Burkett; Rima Koka; Marcia Chien; Sophia Chai; Faye Chan; Averil Ma; David L Boone
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-01       Impact factor: 11.205

4.  Induction of IL-15 by TCR/CD3 aggregation depends on IFN-gamma and protects against apoptosis of immature thymocytes in vivo.

Authors:  P Matthys; H Dooms; P Rottiers; T Mitera; L Overgergh; G Leclercq; A Billiau; J Grooten
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

5.  IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.

Authors:  Emily Y Jen; Nancy J Poindexter; Elizabeth S Farnsworth; Elizabeth A Grimm
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

6.  Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges.

Authors:  Chalet Tan; Thomas A Waldmann
Journal:  Expert Opin Drug Deliv       Date:  2020-05-19       Impact factor: 6.648

7.  Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.

Authors:  Meili Zhang; Wei Ju; Zhengsheng Yao; Ping Yu; Bih-Rong Wei; R Mark Simpson; Rebecca Waitz; Marcella Fassò; James P Allison; Thomas A Waldmann
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

8.  Interleukin-15 enhances proliferation and chemokine secretion of human follicular dendritic cells.

Authors:  Minchan Gil; Seo-Jeong Park; Yoo-Sam Chung; Chan-Sik Park
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

9.  Interleukin-15 may be responsible for early activation of intestinal intraepithelial lymphocytes after oral infection with Listeria monocytogenes in rats.

Authors:  K Hirose; H Suzuki; H Nishimura; A Mitani; J Washizu; T Matsuguchi; Y Yoshikai
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

10.  Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.

Authors:  Jason C Steel; Charmaine A Ramlogan; Ping Yu; Yoshio Sakai; Guido Forni; Thomas A Waldmann; John C Morris
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.